Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Christine L Talarico"'
Autor:
Thomas A. Lutz, Susan Swindells, Vasiliki Chounta, Christine L. Talarico, Jenny Huang, Lelanie van Zyl, Paul D Benn, William Spreen, Kati Vandermeulen, Kimberly Y. Smith, Herta Crauwels, Conn M. Harrington, Essack Mitha, Norma Porteiro, Susan L. Ford, Simon Vanveggel, Matthias Stoll, Kai S Hove, Rodica Van Solingen-Ristea, David A. Margolis, Alyssa Shon
Publikováno v:
AIDS (London, England)
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48 to continuing three-drug dai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2e6b50ecd94d0bfad37aa24f4e93b88
http://europepmc.org/articles/PMC8711605
http://europepmc.org/articles/PMC8711605
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8628b61e4e5a6408b1220516448bebf7
http://europepmc.org/articles/PMC8270504
http://europepmc.org/articles/PMC8270504
Autor:
Miguel García Deltoro, Veerle Van Eygen, Paul D Benn, Kimberly Y. Smith, Hans Jaeger, Parul Patel, Fritz Bredeek, Rodica Van Solingen-Ristea, Christine L. Talarico, William Spreen, Marie-Aude Khuong-Josses, Simon Vanveggel, Susan L. Ford, Gary Richmond, Edgar T. Overton, Giuliano Rizzardini, Krischan J Hudson, Amy Cutrell, Susan Swindells, Vasiliki Chounta, Jaime Andrade-Villanueva, Catherine Orrell, Herta Crauwels, David A. Margolis, Mark S. Shaefer, Firaya Nagimova, Yuanyuan Wang, Alexander Wong
Publikováno v:
The Lancet. 396:1994-2005
Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin furthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba4e7fbadd20f255f1dfaee3cb18f5a3
https://doi.org/10.1016/s0140-6736(20)32666-0
https://doi.org/10.1016/s0140-6736(20)32666-0
Autor:
David A. Margolis, Conn M. Harrington, Krischan J Hudson, Christine L. Talarico, Pedro Cahn, Simon Vanveggel, Fritz Bredeek, Gary Richmond, Wim Louis Julien Parys, Jenny Huang, Giuliano Rizzardini, Herta Crauwels, Vadim Pokrovsky, Parul Patel, Peter Williams, Joseph M. Mrus, Jaime-Federico Andrade-Villanueva, Graham H R Smith, Susan Swindells, Susan L. Ford, Yeon Sook Kim, Gulam H Latiff, Kimberly Y. Smith, Axel Baumgarten, Mar Masiá, Vasiliki Chounta, William Spreen
Publikováno v:
New England Journal of Medicine. 382:1112-1123
Background Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods In this phase ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68dcd06091be99a5f6d22eac2bc73d2b
https://doi.org/10.1056/nejmoa1904398
https://doi.org/10.1056/nejmoa1904398
Autor:
Babafemi O Taiwo, Darrell Tan, Parul Patel, Paula Teichner, Joseph Polli, Louise Garside, Ronald D’Amico, Christine L Talarico, Rodica Van Solingen-Ristea, Bryan Baugh, William Spreen, Michael Aboud, Matthew Bosse
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e32ab926029e2a2624c123148141e7
http://europepmc.org/articles/PMC8644679
http://europepmc.org/articles/PMC8644679
Autor:
Jaime Andrade-Villanueva, Yuanyuan Wang, Christine L. Talarico, David A. Margolis, Anders Thalme, Veerle Van Eygen, Gary Richmond, Susan L. Ford, Kimberly Y. Smith, Elena Belonosova, Rodica Van Solingen-Ristea, Giuliano Rizzardini, Antonio Ocampo Hermida, Rosie Mngqibisa, Paul D Benn, Herta Crauwels, Krischan J Hudson, Hans Jaeger, William Spreen, Faiza Ajana, Edgar T. Overton, Carlos Martin Espanol, Simon Vanveggel
Publikováno v:
The lancet. HIV. 8(11)
Summary Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c19e59d39c2a6853ee818bd4257997a
https://pubmed.ncbi.nlm.nih.gov/34648734
https://pubmed.ncbi.nlm.nih.gov/34648734
Autor:
Jaime Andrade-Villanueva, Amy Cutrell, Joseph M. Mrus, Veerle Van Eygen, William Spreen, Axel Baumgarten, Edgar T. Overton, Mar Masiá, Angela Wills, Susan L. Ford, Sterling Wu, Ken Chow, Giuliano Rizzardini, Vadim Pokrovsky, Keikawus Arastéh, Gulam H Latiff, Chloe Orkin, Sandy Griffith, Ronald D'Amico, Rodica Van Solingen-Ristea, Conn M. Harrington, Herta Crauwels, Shinichi Oka, Christine L. Talarico, Jeremy Roberts, Gary Richmond, Krischan J Hudson, Miguel de Górgolas Hernández-Mora, Susan Swindells, Kimberly Y. Smith, David A. Margolis, Marty St. Clair, Parul Patel, Simon Vanveggel, Pierre Marie Girard, Nicola Walters
Publikováno v:
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Journal of Acquired Immune Deficiency Syndromes (1999)
instname
Journal of Acquired Immune Deficiency Syndromes (1999)
HIV remains a major global health concern, with the Joint United Nations Programme on HIV/AIDS and the World Health Organization (WHO) estimating the number of people living with HIV (PLWH) to be ∼37.9 million in 2018.1,2 Improvements in HIV treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d982fc10553dbbfcbcd25d10d307cb
http://hdl.handle.net/10486/697840
http://hdl.handle.net/10486/697840
Autor:
Sandy Griffith, Ojesh R Upadhyay, Marty St. Clair, William Spreen, Sterling Wu, Conn M. Harrington, Krischan J Hudson, David A. Margolis, Christine L. Talarico, Jan van Lunzen, Veerle Van Eygen
Publikováno v:
Open Forum Infectious Diseases
Background Phase III/IIIb studies demonstrated cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks (Q4W) was noninferior to current antiviral regimen (CAR) (FLAIR and ATLAS) and CAB + RPV LA dosed every 8 weeks (Q8W) was nonin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::716dd89d5bf37b2be01a75fd40ea3da3
https://doi.org/10.1093/ofid/ofaa439.1207
https://doi.org/10.1093/ofid/ofaa439.1207
Autor:
Jianfeng Xu, Anita Scribner, Brian A. Johns, Mark Johnson, Jerry Jeffrey, Viviana Wilches, Moti Ramgopal, Edwin DeJesus, Franco Felizarta, Christine L. Talarico, Jianjun Gan, Paul M. Benson, Roxanne C. Jewell, Etienne Dumont, Fiona Halliday, Sara Duckworth Harward
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 71(5)
Background GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. Methods The phase 2a, proof-of-concept study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379ba8f6e89f8981a98d23226af0f9ce
https://pubmed.ncbi.nlm.nih.gov/31769793
https://pubmed.ncbi.nlm.nih.gov/31769793
Autor:
Kelly E, Dooley, Richard, Kaplan, Noluthando, Mwelase, Beatriz, Grinsztejn, Eduardo, Ticona, Marcus, Lacerda, Omar, Sued, Elena, Belonosova, Mounir, Ait-Khaled, Konstantinos, Angelis, Dannae, Brown, Rajendra, Singh, Christine L, Talarico, Allan R, Tenorio, Michael R, Keegan, Michael, Aboud, Avihingsanon, Anchalee
Publikováno v:
Clinical Infectious Diseases.
The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f3c1f5bef9592dcd9003407e63b1c1
https://doi.org/10.1093/cid/ciz256
https://doi.org/10.1093/cid/ciz256